Strides Pharma to Market WHO-Prequalified Generic Contraceptive DMPA-SC in Africa

Strides Pharma Science announced that one of its subsidiaries will market the world’s first WHO-prequalified generic version of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) across Africa. Developed by Incepta Pharmaceuticals under the brand name Medogen SubQ, the product, supported by the Children’s Investment Fund Foundation (CIFF) and the Gates Foundation, aims to enhance access to affordable reproductive health solutions for women.

Expanding Access to Women’s Health Solutions

The WHO prequalification marks a major milestone in diversifying the global supply of DMPA-SC, breaking the long-standing single-source bottleneck and enabling health systems to procure the contraceptive at reduced prices. DMPA-SC is a three-month, self-administered contraceptive injection designed for discretion and convenience, particularly for women in underserved low- and middle-income regions. With over 250 million women worldwide lacking access to modern contraception, this initiative represents a critical advancement in women’s reproductive rights.

Strengthening Strides’ Women’s Health Portfolio in Africa

Commenting on the milestone, Aditya Kumar, Executive Director – Business Development at Strides, stated that the collaboration with Incepta reinforces the company’s mission to provide safe, high-quality, and affordable contraceptive medicines. The launch strengthens Strides’ Women’s Health franchise in Africa, which already includes popular brands like Vitafer and L-Gest. The initiative underscores Strides’ commitment to empowering women with greater control over their reproductive health and choices.